Wells Fargo says that commentary on Tenet Healthcare’s (THC) earnings call was generally as it would have been expected. Tenet is not yet ready to discuss 2026, including potential impact from enhanced subsidy expiration or jump-off considerations, Wells adds. The firm has an Overweight rating on the shares with a price target of $195.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Morning Movers: Lockheed Martin slips following second quarter report
- Tenet Healthcare reports Q2 adjusted EPS $4.02 ,consensus $2.87
- Tenet Healthcare sees 2025 EPS $15.55-$16.21, consensus $12.84
- Notable companies reporting before tomorrow’s open
- TD says CMS hospital rules positive for Surgery Partners, negative for HCA